JP2024532129A5 - - Google Patents
Info
- Publication number
- JP2024532129A5 JP2024532129A5 JP2024509031A JP2024509031A JP2024532129A5 JP 2024532129 A5 JP2024532129 A5 JP 2024532129A5 JP 2024509031 A JP2024509031 A JP 2024509031A JP 2024509031 A JP2024509031 A JP 2024509031A JP 2024532129 A5 JP2024532129 A5 JP 2024532129A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- therapeutically effective
- subject
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163234973P | 2021-08-19 | 2021-08-19 | |
| US63/234,973 | 2021-08-19 | ||
| US202163251972P | 2021-10-04 | 2021-10-04 | |
| US63/251,972 | 2021-10-04 | ||
| US202163263095P | 2021-10-27 | 2021-10-27 | |
| US63/263,095 | 2021-10-27 | ||
| US202263311622P | 2022-02-18 | 2022-02-18 | |
| US63/311,622 | 2022-02-18 | ||
| US202263371685P | 2022-08-17 | 2022-08-17 | |
| US63/371,685 | 2022-08-17 | ||
| PCT/US2022/040747 WO2023023245A1 (en) | 2021-08-19 | 2022-08-18 | Compounds for treating conditions related to pcsk9 activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024532129A JP2024532129A (ja) | 2024-09-05 |
| JP2024532129A5 true JP2024532129A5 (enExample) | 2025-12-25 |
Family
ID=83319263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024509031A Pending JP2024532129A (ja) | 2021-08-19 | 2022-08-18 | Ｐｃｓｋ９活性に関連する状態を治療するための化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240238367A1 (enExample) |
| EP (1) | EP4387645A1 (enExample) |
| JP (1) | JP2024532129A (enExample) |
| KR (1) | KR20240050369A (enExample) |
| AU (1) | AU2022330007A1 (enExample) |
| CA (1) | CA3228604A1 (enExample) |
| IL (1) | IL310851A (enExample) |
| MX (1) | MX2024002146A (enExample) |
| WO (1) | WO2023023245A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025042927A2 (en) * | 2023-08-24 | 2025-02-27 | Merck Sharp & Dohme Llc | Sustained-release formulations for poorly permeable cyclic peptides |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
| US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
| US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
| US6054587A (en) | 1997-03-07 | 2000-04-25 | Metabasis Therapeutics, Inc. | Indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| US6284748B1 (en) | 1997-03-07 | 2001-09-04 | Metabasis Therapeutics, Inc. | Purine inhibitors of fructose 1,6-bisphosphatase |
| DE69819311T2 (de) | 1997-03-07 | 2004-07-29 | Metabasis Therapeutics Inc., San Diego | Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase |
| KR100818845B1 (ko) | 1998-09-09 | 2008-04-01 | 메타베이시스 테라퓨틱스, 인크. | 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제 |
| AU7705601A (en) | 2000-07-25 | 2002-02-05 | Merck & Co Inc | N-substituted indoles useful in the treatment of diabetes |
| EP1357908A4 (en) | 2001-01-30 | 2009-07-15 | Merck & Co Inc | "ACYLSULFAMIDES FOR THE TREATMENT OF FATIBILITY, DIABETES AND LIPID DISORDERS" |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| CN100457730C (zh) | 2002-08-29 | 2009-02-04 | 默克公司 | 具有抗糖尿病活性的吲哚化合物 |
| EP1546142A4 (en) | 2002-08-29 | 2007-10-17 | Merck & Co Inc | INDOLES HAVING ANTIDIABETIC EFFECT |
| AU2004207444B2 (en) | 2003-01-17 | 2008-07-31 | Merck & Co., Inc. | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| CN101743616B (zh) | 2007-06-28 | 2012-02-22 | 株式会社半导体能源研究所 | 半导体装置的制造方法 |
| CA2691010A1 (en) | 2007-06-28 | 2008-12-31 | Merck Frosst Canada Ltd. | Substituted fused pyrimidines as antagonists of gpr105 activity |
| US20110301079A1 (en) | 2007-09-21 | 2011-12-08 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Neuromedin u receptor agonists and uses thereof |
| IL279363B2 (en) | 2018-06-21 | 2025-12-01 | Merck Sharp & Dohme | Pcsk9 antagonist compounds |
| EP4021919A1 (en) * | 2019-08-30 | 2022-07-06 | Merck Sharp & Dohme Corp. | Pcsk9 antagonist compounds |
-
2022
- 2022-08-18 IL IL310851A patent/IL310851A/en unknown
- 2022-08-18 JP JP2024509031A patent/JP2024532129A/ja active Pending
- 2022-08-18 CA CA3228604A patent/CA3228604A1/en active Pending
- 2022-08-18 KR KR1020247008443A patent/KR20240050369A/ko active Pending
- 2022-08-18 WO PCT/US2022/040747 patent/WO2023023245A1/en not_active Ceased
- 2022-08-18 AU AU2022330007A patent/AU2022330007A1/en active Pending
- 2022-08-18 US US18/684,095 patent/US20240238367A1/en active Pending
- 2022-08-18 EP EP22769816.4A patent/EP4387645A1/en active Pending
- 2022-08-18 MX MX2024002146A patent/MX2024002146A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090297598A1 (en) | Therapeutic combination | |
| US20240189311A1 (en) | Combination Therapy of Obicetrapib and Ezetimibe for Use in Statin Intolerant Patients Suffering from Hyperlipidemia or Mixed Dyslipidaemia | |
| EA032515B1 (ru) | Лечение или профилактика сердечно-сосудистых явлений с использованием колхицина | |
| BRPI1007945B1 (pt) | Formulação farmacêutica de liberação controlada de nitazoxamida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral | |
| CN102056603A (zh) | 决奈达隆用于预防持续性心房纤颤 | |
| JP6068765B2 (ja) | 薬学的複合製剤 | |
| WO2011069326A1 (zh) | 包含阿替洛尔和氨氯地平的双层片剂 | |
| JP2007302657A (ja) | 痙症の兆候および症候の緩和方法 | |
| CN102149377A (zh) | 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途 | |
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| TW202220642A (zh) | 三苯基鈣敏感性化合物之調配物 | |
| JP2024532129A5 (enExample) | ||
| JP2024539476A5 (enExample) | ||
| WO2025059594A1 (en) | METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH) | |
| KR100692235B1 (ko) | 안지오텐신 ⅱ 길항물질의 신규한 용도 | |
| EP4185291B1 (en) | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound | |
| US9675552B2 (en) | Use of stabilized granules containing glyceryl trinitrate for arteriogenesis | |
| JP2025510311A5 (enExample) | ||
| EP2727595B1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| US20080145422A1 (en) | Galantamine tablet formulation | |
| EP2977048A1 (en) | Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor | |
| RU2024106935A (ru) | Соединения для лечения состояний, связанных с pcsk9-активностью | |
| US20050112200A1 (en) | EDTA containing compositions and uses thereof | |
| US20210052608A1 (en) | Methods of treating bacterial infections with minocycline | |
| EP3582786A1 (en) | Co-administration of minocycline and colistin to reduce acute kidney injury |